Trente huit pour cent des répondeurs utilisent des antidotes au cyanure en préhospitalier, qui est OHB12 dans 46% des cas. Le taux de réponse au questionnaire a été de 14% (284/2 000). En plus des réponses, nous avons analysé les données de la « Smoke Inhalation Treatment Database » (STID), banque de données publique abondée par les SU, colligeant le devenir des patients victimes d’une IF et les avons comparées aux données de la littérature, retrouvée dans PubMed. La « Fire Smoke Coalition Newsletter » a proposé par courriel aux services d’urgence abonnés un étude sur l’utilisation d’OHB12, basée sur le volontariat. Les buts de cette étude était de caractériser l’utilisation préhospitalière d’OHB12 à travers les données des services d’urgences (SU) et de rapporter une série de cas issus de leurs dossiers. L’utilisation préhospitalière de l’hydroxocobalamine (OHB12) comme antidote du cyanure, intoxication grave compliquant les inhalations de fumées (IF), n’est toujours pas réalisée partout aux États-Unis, bien que son innocuité et son efficacité aient été démontrées dès 2006. This survival rate is significantly greater than those reported previously. Although a small sample, patients who received prehospital hydroxocobalamin had improved survival. Prehospital administration of hydroxocobalamin for cyanide toxicity is uncommon in the United States, as evidenced by this analysis, despite well-documented safety and efficacy. Other studies found a survival rate of 72% and 42% after administration of hydroxocobalamin for smoke inhalation. For the SITD, 12 of 13 (92%) patients who received hydroxocobalamin for suspected inhalation survived. 20% of responders reported a formal ALS protocol was in place for hydroxocobalamin use. Only 38% reported prehospital utilization of a hydrogen cyanide antidote with 46% using hydroxocobalamin. The survey had a 14% response rate (284/2000). Analysis was compared to current published data from PubMed. Survey responses were analyzed in addition to survival data from the Smoke Inhalation Treatment Database (SITD), a publically available, self-reported, online database for EMS regarding smoke inhalation patient outcomes. The Fire Smoke Coalition Newsletter emailed a voluntary survey to EMS subscribers regarding hydroxocobalamin use. The purpose of this study was to characterize practices of prehospital hydroxocobalamin administration via a survey of emergency medical services (EMS) and to report a case series from an EMS database to track use of hydroxocobalamin. Prehospital use of hydroxocobalamin as an antidote for cyanide toxicity, a serious complication of smoke inhalation, has yet to be universally adopted in the United States though its efficacy and safety have been demonstrated since 2006.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |